BlueCrest Capital Management’s Halozyme HALO Stock Holding History

BlueCrest Capital Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,934	Closed	-$199K	–	1093
2018 Q3	$199K	Buy	+10,934	New	+$192K	0.01%	1275
2018 Q2	–	Sell	-10,394	Closed	-$204K	–	1624
2018 Q1	$204K	Buy	+10,394	New	+$201K	0.01%	1272

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

BlueCrest Capital Management's HALO Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Halozyme (HALO) in Q4 2018, closing a stake of 10,934 shares — an estimated $199K sold.

BlueCrest Capital Management first reported a position in HALO in Q1 2018 and held it in 2 quarters. The position peaked at $204K in Q1 2018. 195 funds tracked by Wall St. Rank hold HALO as of Q4 2018.

BlueCrest Capital Management reported no remaining Halozyme position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 10,934 Halozyme shares in Q4 2018, an estimated $199K.
BlueCrest Capital Management first reported a position in Halozyme in Q1 2018 and held it in 2 quarters.
BlueCrest Capital Management's Halozyme position peaked at $204K in Q1 2018.
195 funds tracked by Wall St. Rank held Halozyme as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.